The FDA has approved a third indication for a fixed-dose combination of ceftazidime and avibactam to treat adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).
The newest indication is for HABP/VABP caused by susceptible gram-negative bacteria including Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Pseudomonas aeruginosa, and Haemophilus influenzae.
Voelker R. New Treatment Option for Pneumonia. JAMA. 2018;319(11):1086. doi:10.1001/jama.2018.1812
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: